NDAINHALATIONAEROSOL, METERED
Approved
Apr 2016
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1
Data completeness
7/8 — Comprehensive
BEVESPI AEROSPHERE (glycopyrrolate and formoterol fumarate) by AstraZeneca is fumarate. Approved for copd, asthma, chronic obstructive pulmonary disease. First approved in 2016.
Drug data last refreshed 9h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BEVESPI AEROSPHERE is a combination inhalation aerosol containing glycopyrrolate (long-acting anticholinergic) and formoterol fumarate (long-acting beta-2 agonist) for maintenance treatment of COPD. The dual mechanism provides bronchodilation through M3 receptor antagonism in airway smooth muscle plus beta-2 adrenergic stimulation, addressing complementary pathophysiologic mechanisms in chronic obstructive pulmonary disease.
$67MPart D
PeakStable
4.5 years to LOEProduct is in peak commercial phase with 118K+ annual claims, supporting a sustained sales and medical affairs footprint through 2030.
Mechanism of Action
fumarate. The mechanism of action described below for the individual components applies to BEVESPI AEROSPHERE. These drugs represent two different classes of medications (an anticholinergic, and a long-acting selective beta 2 -adrenoceptor agonist) that have different effects on clinical physiology…
Worked on BEVESPI AEROSPHERE at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.